Patents Examined by D. Margaret M. Mach
  • Patent number: 5571822
    Abstract: A method of inhibiting tumor-cell growth in a mammalian subject, by administering a therapeutically effective amount of a selected 2-phenyl-4-quinolone compound. The selected compound shows unexpectely high activity against a variety of solid tumor cells.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: November 5, 1996
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Kuo-Hsiung Lee, Sheng-Chu Kuo, Tian-Shung Wu, Hui K. Wang, Leping Li
  • Patent number: 5561141
    Abstract: Compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are herein described, A is a straight or branched (C.sub.2 -C.sub.12)alkyl or a phenyl moiety and B is a moiety of the formula: ##STR2## The compounds are effective in potentiating the activity of chemotherapeutic anti-cancer agents by increasing the sensitivity of multi-drug resistant cells to such chemotherapeutic agents.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: October 1, 1996
    Assignee: American Cyanamid Company
    Inventors: Dennis Powell, Rolf Paul, William A. Hallett, Dan M. Berger, Minu D. Dutia
  • Patent number: 5561144
    Abstract: The present invention is directed to a new 5HT.sub.2 antagonist, (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol, and its use in the treatment of a number of disease states.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: October 1, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Albert A. Carr, John M. Kane, David A. Hay, Christopher J. Schmidt
  • Patent number: 5556978
    Abstract: 1R-cis, 1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis-(1,2,3,4-tetrahydro-6,7-dimet hoxy-2-methyl-1-veratrylisoquinolinium) salt, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockade, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockade), in comparison with the known mixture of geometrical and optical isomers.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: September 17, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Derek A. Hill, Geoffrey L. Turner
  • Patent number: 5556863
    Abstract: The present invention relates to novel quinoline derivatives of the formula ##STR1## which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: September 17, 1996
    Assignee: Astra Aktiebolag
    Inventor: Carl I. Starke
  • Patent number: 5554756
    Abstract: Compositions containing compounds ##STR1## and their pharmaceutically acceptable acid addition salts inhibit proteases of viral origin and can be used as medicaments for the treatment or prophylaxis of viral infections. They can be manufactured according to generally known procedures.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: September 10, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Balraj K. Handa, Peter J. Machin, Joseph A. Martin, Sally Redshaw, Gareth J. Thomas
  • Patent number: 5552410
    Abstract: Compounds of the formula: ##STR1## in which R represents a chlorine atom or a hydroxyl group and R.sub.4 represents a (C.sub.1 -C.sub.4)alkyl group in the R or S form are useful as synthetic intermediates.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: September 3, 1996
    Assignee: Synthelabo
    Inventors: Daniel Galtier, Gilbert Lassalle
  • Patent number: 5550149
    Abstract: Compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are herein described, A is a straight or branched (C.sub.2 -C.sub.12)alkyl or a phenyl moiety and B is a moiety of the formula: ##STR2## The compounds are effective in potentiating the activity of chemotherapeutic anti-cancer agents by increasing the sensitivity of multi-drug resistant cells to such chemotherapeutic agents.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: August 27, 1996
    Assignee: American Cyanamid Company
    Inventors: Dennis Powell, Rolf Paul, William A. Hallett, Dan M. Berger, Minu D. Dutia
  • Patent number: 5547978
    Abstract: The invention relates to derivatives of pyrrolidin-2-ylcarbonylheterocyclic compound of the general formula ##STR1## in which R.sup.1 represents C.sub.1-6 alkyl, C.sub.1-20 cycloalkyl, aryl or heteroaryl,R.sup.2 represents a heterocyclic compound selected from the group consisting of 2-thiazole, 2-oxazole, 2-imidazole, 2-pyrrole, 2-thiophene, 2-benzothiazole, 2-benzoxazole, 2-benzimidazole, 2-indole, 2-thiazolo[5,4-b]pyridine, 2-oxazolo[4,5-b]pyridine, 2-imidazo[4,5-b]pyridine, 5-thiazole, 2-thiazoline, 2-pyridine, 3-pyridine, 5-pyrimidine, 2-pyrazine, 2-triazole or 2-pyrazole wherein the heterocyclic compound may be unsubstituted or substituted independently with R.sup.4 or R.sup.5 wherein R.sup.4 and R.sup.5 are H, C.sub.1-5 alkyl, aryl or R.sup.4 and R.sup.
    Type: Grant
    Filed: November 23, 1994
    Date of Patent: August 20, 1996
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Burton G. Christensen, Takashi Egawa, Yasuyuki Ichimaru, Shokichi Ohuchi, Tsuneo Okonogi, Arthur A. Patchett, Seiji Shibahara, Seiji Tsutsumni
  • Patent number: 5547962
    Abstract: A 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative represented by the general formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a lower alkyl group; R.sup.2 is a hydrogen atom, a lower alkyl group, a lower alkanoyl group, a halogenated lower alkanoyl group or a residue of carboxylic acid ester; R.sup.3 is a hydrogen atom or a lower alkyl group; R.sup.4, R.sup.5 or R.sup.6 are each independently a hydrogen atom or a lower alkyl group; or two of R.sup.4, R.sup.5 and R.sup.6 may be taken together to form a --(CH.sub.2).sub.n -group wherein n is 1 or 2, a stereoisomer thereof, or a pharmacologically acceptable salt thereof, the process for preparing these compounds, a pharmaceutical composition comprising an effective amount of these compounds and methods for the treatment of infectious diseases through the administration to patients of an effective amount of these compounds, and intermediates of these compounds are disclosed. These compounds are effective as antibacterial agents.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: August 20, 1996
    Assignee: Horuriku Seiyaku Co., Ltd.
    Inventors: Yasuo Ito, Hideo Kato, Singo Yasuda, Noriyuki Kado, Toshihiko Yoshida, Yoichi Yamamoto
  • Patent number: 5543420
    Abstract: A quinoline-3-acetic acid derivative of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are the same or different and each is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, a halogen atom or a substituted or unsubstituted lower alkyl, R.sup.5 is an optionally esterified carboxyl and the broken line means an optional presence of a double bond, and a pharmaceutically acceptable salt thereof. The novel compound of the formula (I) and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory activity in mammals inclusive of human and are highly safe. Accordingly, they are useful as pharmaceutical compositions for the treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly cataract and neurosis.
    Type: Grant
    Filed: November 1, 1994
    Date of Patent: August 6, 1996
    Assignees: The Green Cross Corporation, Senju Pharmaceutical Co., Ltd.
    Inventors: Tomoji Aotsuka, Toshiyuki Nishio, Hiroshi Hosono, Yoshiyuki Nakamura, Tetsuo Matsui, Hiromichi Ishikawa
  • Patent number: 5541332
    Abstract: A process for the preparation of a chloropyridine of the formula ##STR1## which comprises reacting an enamide of the formula ##STR2## with a chlorinating agent in the presence of a di-substituted formamide ##STR3## in which R.sup.4 and R.sup.5 each individually is alkyl or cycloalkyl or together are alkanediyl, at a temperature between about -30.degree. C. and 100.degree. C., thereby to produce a compound of the formula ##STR4## and subjecting said compound to thermal cleavage. Compounds I are novel. Compounds IV are known intermediates for agrochemicals and pharmaceuticals.
    Type: Grant
    Filed: January 4, 1995
    Date of Patent: July 30, 1996
    Assignee: Bayer Aktiengesellschaft
    Inventors: Reinhard Lantzsch, Klaus Jelich, Carl Casser, Christoph Mannheims, Knud Lawrenz
  • Patent number: 5541196
    Abstract: Substituted quinolines having formula (1), wherein R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 each independently represent a hydrogen atom, a linear or branched C.sub.1-7 alkyl, alkenyl, epoxy-alkyl or mono/polyalcohol group; an amine group or an amide group, an OR group in which R is hydrogen or a C.sub.1-7 alkyl or alkenyl group or a phenyl group; and R.sub.2 is an OR group in which R is as defined above, or a C.sub.1-7 alkyl alkenyl or epoxyalkyl group, a phenyl, phenol, methylenedioxyphenyl, or dimethoxyphenyl group, or a C.sub.1-7 alkyl, alkenyl or epoxyalkyl group, a phenyl, phenol, methylenedioxyphenyl, or dimethoxphenyl group or a C.sub.1-7 alkyl, alkenyl or epoxy-alklyl group comprising at least one of the following substituents: a C.sub.1-4 alkyl or alkenyl group; a phenyl, phenol, dimethylphenyl, dimethoxyphenyl or methylenedioxphenyl group; or an OR group in which R is hydrogen or a C.sub.1-4 alkyl or alkenyl group; or an NHR group in which R is hydrogen or a C.sub.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: July 30, 1996
    Assignee: Institut Francais de Recherche Scientifique Pour le Developpment en Cooperation (ORSTOM)
    Inventors: Alain Fournet, Alcira Angelo Barrios, Victoria Munoz, Reynald Hocquemiller, Fran.cedilla.ois Roblot, Jean Bruneton, Pascal Richomme, Jean Charles Gantier
  • Patent number: 5541190
    Abstract: This invention relates to hexa- and octahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: July 30, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Kenneth S. Hirsch, Charles D. Jones, David E. Lawhorn, Loretta A. McQuaid, Leland O. Weigel
  • Patent number: 5532266
    Abstract: Novel arylacetamides of the formula I ##STR1## in which Q is R.sup.4 --CH(CH.sub.2 Z)--NA--, ##STR2## R.sup.1 is Ar, cycloalkyl with 3-7 C atoms or C.sub.4 -C.sub.8 -cycloalkyl-C.sub.1 -C.sub.7 -alkyl,R.sup.2 is Ar,R.sup.3 is H, OH, OA or A,R.sup.4 is A or phenyl which can optionally be substituted once or twice by F, Cl, Br, I, OH, OA, CF.sub.3, NO.sub.2, NH.sub.2, NHA, NHCOA, NHSO.sub.2 A or NA.sub.2,R.sup.5 and R.sup.6 are each, independently of one another, H, F, Cl, Br, I, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA, NHCONH.sub.2, NO.sub.2 or taken together are methylenedioxy,A is alkyl with 1-7 C atoms, and physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 2, 1996
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Rudolf Gottschlich, Karl-August Ackermann, Helmut Prucher, Christoph Seyfried, Hartmut Greiner, Gerd Bartoszyk, Frank Mauler, Manfred Stohrer, Andrew Barber
  • Patent number: 5530132
    Abstract: Novel 2-alkyl carbino1 derivatives of deoxynojirimycin (DNJ) and the chemical synthesis of these derivatives and intermediates therefor from DNJ and their method of inhibiting lentiviruses are disclosed.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: June 25, 1996
    Assignee: G. D. Searle & Co.
    Inventors: Ish K. Khanna, Richard A. Mueller, Richard M. Weier
  • Patent number: 5527809
    Abstract: Substituted imidazo[4,5-b]pyridines and benzimidazoles are prepared by reacting imidazo[4,5-b]pyridines or benzimidazoles with appropriately substituted benzyl halides. The substituted imidazo[4,5-b]pyridines or benzimidazoles can be employed as active compounds in medicaments, in particular for the treatment of arterial hypertension and atherosclerosis.
    Type: Grant
    Filed: January 27, 1994
    Date of Patent: June 18, 1996
    Assignee: Bayer Aktiengesellschaft
    Inventors: Matthias Muller-Gliemann, Jurgen Dressel, Peter Fey, Rudolf H. Hanko, Walter Hubsch, Thomas Kramer, Ulrich E. Muller, Martin Beuck, Stanislav Kazda, Stefan Wohlfeil, Andreas Knorr, Johannes-Peter Stasch, Siegfried Zaiss
  • Patent number: 5525727
    Abstract: The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:(a) compounds of the formula[D-DHC] (I)wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic-stimulant, steroid sex hormone or long chain alkanol; and(b) non-toxic pharmaceutically acceptable salts of compounds of formula (I). The corresponding ionic pyridinium salt type drug/carrier entities [D-QC].sup.+ X.sup.- are also disclosed.
    Type: Grant
    Filed: October 28, 1992
    Date of Patent: June 11, 1996
    Assignee: University of Florida
    Inventor: Nicholas S. Bodor
  • Patent number: 5523407
    Abstract: A quinoline derivative of the formula (I): ##STR1## wherein each phenyl ring of A and B can have one or more substituents; X is ##STR2## (R.sup.1 is a hydrogen atom, a lower alkyl group or a lower alkoxy group) or ##STR3## (R.sup.2 is a hydrogen atom or a lower alkyl group); Y is --(CH.sub.2).sub.m --(m is 0, 1 or 2) or --CH.dbd.CH--, Z is a group of the formula: ##STR4## wherein each phenyl ring of C and D can have one or more substituents, R.sup.3 and R.sup.4 are each a hydrogen or halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.5 is a halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.6 and R.sup.7 are each a hydrogen atom or a lower alkyl group, and n, o and p are each 1 or 2; l is 0 or 1; or its salt, which is useful as a drug for atherosclerosis.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: June 4, 1996
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Kanji Meguro, Hitoshi Ikeda
  • Patent number: 5523406
    Abstract: Novel 2-alkyl carbinol derivatives of deoxynojirimycin (DNJ) and the chemical synthesis of these derivatives and intermediates therefor from DNJ and their method of inhibiting lentiviruses are disclosed.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: June 4, 1996
    Assignee: G. D. Searle & Co.
    Inventors: Ish K. Khanna, Richard A. Mueller, Richard M. Weier